New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder

McEwen BS, Milner TA. Understanding the broad influence of sex hormones and sex differences in the brain. J Neurosci Res. 2017;95(1–2):24–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci. 2015;9:37.

Article  PubMed  PubMed Central  Google Scholar 

Dubol M, et al. Neuroimaging the menstrual cycle: a multimodal systematic review. Front Neuroendocrinol. 2021;60: 100878.

Article  CAS  PubMed  Google Scholar 

Sundstrom-Poromaa I, et al. Progesterone—friend or foe? Front Neuroendocrinol. 2020;59: 100856.

Article  PubMed  Google Scholar 

Bixo M, et al. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 1997;764(1–2):173–8.

Article  CAS  PubMed  Google Scholar 

Rubinow DR, Schmidt PJ. Sex differences and the neurobiology of affective disorders. Neuropsychopharmacology. 2019;44(1):111–28.

Article  PubMed  Google Scholar 

Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. In Feingold KR et al (editor) Endotext . 2000: South Dartmouth (MA).

Backstrom T, et al. Allopregnanolone and mood disorders. Prog Neurobiol. 2014;113:88–94.

Article  CAS  PubMed  Google Scholar 

Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218(1):68–74.

Article  PubMed  Google Scholar 

Eisenlohr-Moul T, et al. Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with premenstrual dysphoric disorder. BMC Psychiatry. 2022;22(1):199.

Article  PubMed  PubMed Central  Google Scholar 

Wikman A, et al. Prevalence and correlates of current suicidal ideation in women with premenstrual dysphoric disorder. BMC Womens Health. 2022;22(1):35.

Article  PubMed  PubMed Central  Google Scholar 

Schoep ME, et al. The impact of menstrual symptoms on everyday life: a survey among 42,879 women. Am J Obstet Gynecol. 2019;220(6):569 e1–e7.

Hantsoo L, et al. Premenstrual symptoms across the lifespan in an international sample: data from a mobile application. Arch Womens Ment Health. 2022;25(5):903–10.

Article  PubMed  PubMed Central  Google Scholar 

Sveindottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand. 2000;79(5):405–13.

CAS  PubMed  Google Scholar 

Wittchen HU, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002;32(1):119–32.

Article  PubMed  Google Scholar 

A.P.A., Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5) 2013.

Epperson CN, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry. 2012;169(5):465–75.

Article  PubMed  PubMed Central  Google Scholar 

Halbreich U, et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28(Suppl 3):1–23.

CAS  PubMed  Google Scholar 

Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause Int. 2011;17(3):96–101.

Article  PubMed  Google Scholar 

Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci. 2008;33(4):291–301.

PubMed  PubMed Central  Google Scholar 

Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. Med Clin North Am. 2019;103(4):613–628.

Comasco E, Sundstrom-Poromaa I. Neuroimaging the menstrual cycle and premenstrual dysphoric disorder. Curr Psychiatry Rep. 2015;17(10):77.

Article  PubMed  Google Scholar 

Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41–9.

Article  CAS  PubMed  Google Scholar 

Eisenlohr-Moul TA, et al. Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the carolina premenstrual assessment scoring system (C-PASS). Am J Psychiatry. 2017;174(1):51–9.

Article  PubMed  Google Scholar 

Osborn E, et al. Women’s experiences of receiving a diagnosis of premenstrual dysphoric disorder: a qualitative investigation. BMC Womens Health. 2020;20(1):242.

Article  PubMed  PubMed Central  Google Scholar 

Bäckström T, et al. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med. 1983;45(6):503–7.

Yang Q, et al. Association between adverse childhood experiences and premenstrual disorders: A cross-sectional analysis of 11,973 women. BMC Med. 2022;20(1):60.

Article  PubMed  PubMed Central  Google Scholar 

Kulkarni J, et al. The prevalence of early life trauma in premenstrual dysphoric disorder (PMDD). Psychiatry Res. 2022;308: 114381.

Article  PubMed  Google Scholar 

Jahanfar S, Lye MS, Krishnarajah IS. The heritability of premenstrual syndrome. Twin Res Hum Genet. 2011;14(5):433–6.

Article  PubMed  Google Scholar 

Kendler KS, et al. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry. 1998;155(9):1234–40.

Article  CAS  PubMed  Google Scholar 

Jovanovic H, et al. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res. 2006;148(2–3):185–93.

Article  CAS  PubMed  Google Scholar 

Majewska MD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232(4753):1004–7.

Article  CAS  PubMed  Google Scholar 

Bixo M, et al. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. J Neuroendocrinol, 2018;30(2).

Timby E, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology. 2006;186(3):414–24.

Article  CAS  PubMed  Google Scholar 

Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol Stress. 2020;12: 100213.

Article  PubMed  PubMed Central  Google Scholar 

Timby E, et al. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology. 2016;233(11):2109–17.

Article  CAS  PubMed  Google Scholar 

Epperson CN, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2002;59(9):851–8.

Article  CAS  PubMed  Google Scholar 

Amin Z, Canli T, Epperson CN. Effect of estrogen-serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev. 2005;4(1):43–58.

Article  PubMed  Google Scholar 

Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44(9):839–50.

Article  CAS  PubMed  Google Scholar 

Schmidt PJ, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209–16.

Article  CAS  PubMed  Google Scholar 

Schmidt PJ, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174(10):980–9.

Article  PubMed  PubMed Central  Google Scholar 

Segebladh B, et al. Evaluation of different add-back oestradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obst Gynecol 2009;201(2).

Naheed B, O’Brien S. Non-contraceptive estrogen-containing preparations for premenstrual syndrome: a systematic review. Bjog Int J Obst Gynaecol. 2013;120:487–487.

Google Scholar 

Brown J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009(2);CD001396.

Marjoribanks J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013(6);Cd001396.

Harmer CJ, Cowen PJ. ’It’s the way that you look at it’—a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615):20120407.

Article  PubMed  PubMed Central  Google Scholar 

Eriksson E, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol. 2008;28(2):195–202.

Article  CAS  PubMed 

留言 (0)

沒有登入
gif